Kai‐Yan Liu
About
In The Last Decade
Kai‐Yan Liu
455 papers receiving 8.5k citations
Hit Papers
Peers
Comparison fields: 5 of 127
- Hematology 6.5k
- Immunology 2.5k
- Oncology 2.2k
- Public Health, Environmental and Occupational Health 2.0k
- Genetics 1.1k
Countries citing papers authored by Kai‐Yan Liu
This map shows the geographic impact of Kai‐Yan Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai‐Yan Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai‐Yan Liu more than expected).
Fields of papers citing papers by Kai‐Yan Liu
This network shows the impact of papers produced by Kai‐Yan Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai‐Yan Liu. The network helps show where Kai‐Yan Liu may publish in the future.
Co-authorship network of co-authors of Kai‐Yan Liu
This figure shows the co-authorship network connecting the top 25 collaborators of Kai‐Yan Liu. A scholar is included among the top collaborators of Kai‐Yan Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kai‐Yan Liu. Kai‐Yan Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 0 | |
| 6 | 2 | |
| 7 | 2 | |
| 8 | 1 | |
| 9 | 11 | |
| 10 | 3 | |
| 11 | 10 | |
| 12 | 22 | |
| 13 | 115 | |
| 14 | 1 | |
| 15 | 0 | |
| 16 | 46 | |
| 17 | [Cytomegalovirus specific cytotoxic T lymphocytes for treatment of refractory cytomegalovirus infection in patients following allogeneic hematopoietic stem cell transplantation]. | 5 |
| 18 | [The efficacy and safety of recombinant human granulocyte colony stimulating factor primed donor peripheral cell harvest in treatment of poor graft function after allogeneic stem cell transplantation]. | 4 |
| 19 | [Etiological analysis of fever in the first 24 hours following allogeneic peripheral stem cell transfusion]. | 4 |
| 20 | Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic stem cell transplantation: a prospective multi-center trial. | 7 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.